5 completed. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 1 | Completed 1 |
Follow Urinary Bladder Cancer: new trials by email Literature Review of Urinary Bladder Cancer trials Research Report on Urinary Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of NanoDoce® in Participants With Urothelial Carcinoma NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care - Bladder Cancer, Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | NanOlogy, LLC | 36 | 2019-04-02 | 2023-08-14 |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer NEO-PV-01, Nivolumab, Adjuvant - Urinary Bladder Cancer, Bladder Tumors | Phase 1 | Completed | BioNTech US Inc. | 34 | 2016-10-01 | 2021-02-25 |
| Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 - Urinary Bladder Cancer | Phase 1 | Completed | Taris Biomedical LLC | 23 | 2016-05-31 | 2023-09-18 |
| Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 - Urinary Bladder Cancer | Phase 1 | Completed | Taris Biomedical LLC | 12 | 2016-01-01 | 2020-03-10 |
| Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography Injection of 68Ga-NOTA-AE105, Positron Emission Tomography scans - Breast Cancer, Prostate Cancer | Phase 1 | Completed | Copenhagen University Hospital, Rigshospitalet | 10 | 2015-05-01 | 2015-08-24 |
Urinary Bladder Neoplasms (5) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Lung Neoplasms (1) · Melanoma (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Prostatic Neoplasms (1) · Skin Neoplasms (1) · Urogenital Neoplasms (1) · Urologic Neoplasms (1)
Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Male Urogenital Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Urinary Bladder Diseases (5) · Urogenital Diseases (5) · Urologic Diseases (5) · Urogenital Neoplasms (4) · Urologic Neoplasms (4) · Neoplasms by Histologic Type (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Breast Diseases (1) · Bronchial Neoplasms (1)
Adjuvants, Pharmaceutic (1) · Administration, Intravesical (1) · Docetaxel (1) · Neoadjuvant Therapy (1) · Nivolumab (1) · Positron-Emission Tomography (1) · poly ICLC (1)
Taris Biomedical LLC (2) · BioNTech US Inc. (1) · Copenhagen University Hospital, Rigshospitalet (1) · NanOlogy, LLC (1)
United States (3) · Netherlands (2) · Denmark (1)
Donald Lamm, MD, FACS (1) · Dorthe Skovgaard, MD, PhD (1) · Johannes Witjes, MD (1) · Mark DeMario, MD (1) · Siamak Daneshmand, MD (1)
PMID 22213823, PMID 33064988, PMID 33294862, PMID 35431132
2014 (1), 2016 (1)